Nishioka, Yasuhiko

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations

Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 643

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Wang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., et al. (2009) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 297

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 93

Thymidine catabolism as a metabolic strategy for cancer survival

Tabata, S., Yamamoto, M., Goto, H., Hirayama, A., Ohishi, M., Kuramoto, T., Mitsuhashi, A., Ikeda, R., Haraguchi, M., Kawahara, K., et al. (2017) · Cell Reports

Cancer, Hypoxia, and MetabolismBiochemical and Molecular Research

Cited by 68

Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition

Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 12

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial

Maher, T. M., Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., Selman, M., Song, J. W., Ittrich, C., Diefenbach, C., Stowasser, S., et al. (2024) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 7

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis

Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., White, E. S., Ittrich, C., Diefenbach, C., Rohr, K. B., Selman, M., & Maher, T. M. (2024) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 6